Skip to main content

Regeneron Pharmaceuticals(REGN-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low771.34
Day High788.69
Open:781.67
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

TOP STORIES: Regeneron Pharmaceuticals

Select a category then submit the form to load news
GlobeNewswire
Regeneron Science Talent Search 2026 Recognizes America’s Top Young Scientists, Awarding More Than $1.8 Million to High School Seniors for Innovative Research in Computational Mathematics, Neural Science, and Blood Cancer Treatment
Tipranks
Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL), Hims & Hers Health (HIMS) and Regeneron (REGN)
GlobeNewswire
Olatorepatide Obesity Treatment Licensed by Regeneron Demonstrates Positive Phase 3 Results in Chinese Patients
Motley Fool
2 Underrated Weight Loss Stocks to Buy Now
StockStory
1 Nasdaq 100 Stock to Consider Right Now and 2 We Brush Off
AAPL
GlobeNewswire
Regeneron Announces Investor Conference Presentation
Tipranks
Regeneron and Sanofi Complete Key Dupilumab Pregnancy Safety Study With Fresh Data Update
Motley Fool
2 Biotech Giants to Buy in 2026
Zacks Investment Research
Bayer Q4 Earnings Match Estimates, Xarelto and Eylea Pull Down Sales
Bayer Q4 Earnings Match Estimates, Xarelto and Eylea Pull Down Sales
Zacks Investment Research
Novartis' Rhapsido Gets Positive CHMP Opinion for Urticaria in EU
Novartis' Rhapsido Gets Positive CHMP Opinion for Urticaria in EU
Zacks Investment Research
Roche's BTK Drug Fenebrutinib Shines in Multiple Sclerosis Study
Roche's BTK Drug Fenebrutinib Shines in Multiple Sclerosis Study
Tipranks
Regeneron (REGN) Receives a Hold from RBC Capital
GlobeNewswire
Dupixent® (dupilumab) Recommended for EU Approval to Treat Chronic Spontaneous Urticaria (CSU) in Young Children with Ongoing Symptoms Despite Treatment
GlobeNewswire
Regeneron Renews Sponsorship of the Regeneron Science Talent Search Through 2036, Committing an Additional $150 Million to Empower the Next Generation of Science and Technology Leaders
Tipranks
Wall Street Analysts Are Bullish on Top Healthcare Picks
Motley Fool
2 Reasons Regeneron Stock Could Crush the Market for the Next 10 Years
GlobeNewswire
Dupixent® (dupilumab) Approved in the U.S. as the First and Only Medicine for Allergic Fungal Rhinosinusitis (AFRS)
Tipranks
Canaccord Genuity Remains a Buy on Regeneron (REGN)
Motley Fool
1 No-Brainer Biotech Stock To Buy Today and Never Sell
Tipranks
Citi Reaffirms Their Buy Rating on Regeneron (REGN)
GlobeNewswire
Garetosmab Biologics License Application Accepted for FDA Priority Review for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)
Tipranks
Canaccord Genuity Reaffirms Their Buy Rating on Regeneron (REGN)
Tipranks
Regeneron Advances REGN7508 Into Phase 3 To Tackle Cancer-Linked Blood Clots
Tipranks
Sanofi and Regeneron Advance Itepekimab Bet With Completed Phase 2 Bronchiectasis Trial
StockStory
1 Healthcare Stock Worth Your Attention and 2 Facing Challenges
REGN
Zacks Investment Research
Will Eylea Sales Decline Weigh on REGN's Top Line in 2026?
Will Eylea Sales Decline Weigh on REGN's Top Line in 2026?
GlobeNewswire
Regeneron Announces Investor Conference Presentations
Tipranks
Regeneron and Sanofi Advance Kevzara Into Polymyalgia Rheumatica, Eyeing New Growth Channel
Tipranks
RBC Capital Sticks to Their Hold Rating for Regeneron (REGN)
GlobeNewswire
Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI, Showcasing Novel Approaches to Treating Allergy
Tipranks
Regeneron’s REGN9533 Trial Completion Signals Quiet but Important Progress in Clot-Blocking Drugs
Tipranks
Regeneron Targets Early Myeloma: New Phase 3 Trial Pits Linvoseltamab Against Daratumumab

Profile

Regeneron is a biotechnology company focused on the discovery, development and commercialization of treatments targeting serious medical conditions. The company's portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Libtayo, Evkeeza, Inmazeb Arcalyst and Zaltrap. The company also developed an antibody cocktail for COVID-19, REGEN-COV. REGEN-COV is a cocktail of two monoclonal antibodies and was designed specifically to block the infectivity of SARS-CoV-2, the virus that causes COVID-19. Regeneron has a collaboration agreement with Roche for the same. While Regeneron has co-developed Eylea with Bayer's HealthCare unit, Praluent was co-developed with Sanofi. Regeneron collaborated with Bayer for the joint development and commercialization of co-formulated combinations of Eylea, rinucumab and nesvacumab for the treatment of ocular diseases or disorders outside the United States.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.